During the corresponding time, Corcept Therapeutics Inc recorded a revenue increase by 31.74 % year on year, sequentially revenue grew by 55.33 %. While revenue at the Corcept Therapeutics Inc's corporate clients
Corcept Therapeutics Inc's Comment on Sales, Marketing and Customers
Pharmaceutical and biotechnology companies are subject to regulatory statutes governing the promotion and marketing of their products. These companies engage with federal health care programs and healthcare providers, including physicians, pharmacies, teaching hospitals, and various practitioners such as doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants, and certified nurse midwives. Under the federal Physician Payments Sunshine Act, drug manufacturers are required to report payments or transfers of value made to these healthcare organizations and practitioners.
Promising Advances in Ovarian Cancer Treatment Corcept Therapeutics, a company known for its work in endocrinologic and oncologic treatments, recently unveiled promising data from its Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) conference. The study focused on the efficacy of relacorilant combined with nab-paclitaxel in treating patients with platinum-resistant ovarian cancer, which had previously been treated with PARP inhibitors. This development could mark a significant advancement in addressing a challenging form of ovarian cancer, providing hope for patients with limited options. Understanding the Treatment and Trial Relacorilant, in combination with nab-paclitaxel, w...
Advancing Therapeutics in ALS: Corcept s Promising Phase 2 Results for Dazucorilant In an exciting development for the treatment of Amyotrophic Lateral Sclerosis (ALS), Corcept Therapeutics Incorporated recently unveiled promising results from their Phase 2 study of dazucorilant at the European Network to Cure ALS (ENCALS) 2025 annual meeting. This marks a significant milestone for Corcept, a commercial-stage company recognized for its innovative work in modulating the effects of cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders.The DAZALS study is a pivotal exploration into the potential of dazucorilant, a cortisol modulator, in altering the disease trajectory of ALS, ...
In a significant stride towards addressing the unmet medical needs of patients suffering from Amyotrophic Lateral Sclerosis (ALS), Corcept Therapeutics Incorporated has unveiled promising results from its Phase 2 DAZALS study. This randomized, double-blind, placebo-controlled trial investigated the safety and efficacy of two doses 150 mg and 300 mg of Dazucorilant, a selective modulator of cortisol, in ALS patients. ALS, a progressive neurodegenerative disease, is characterized by the degeneration of motor neurons, leading to muscle weakness and eventual paralysis. The challenge in treating ALS lies not only in symptom management but also in modification of disease progression. Corcept, drawing on its expert...
Corcept Announces Results from Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association s Scientific SessionsCorcept Therapeutics Incorporated recently revealed the findings from the prevalence phase of its CATALYST study at the American Diabetes Association s 84th Scientific Sessions. The study focused on hypercortisolism, specifically Cushings syndrome, in patients with difficult-to-control type 2 diabetes. Corcept is a commercial-stage company that specializes in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by manipulating the effects of the hormone cortisol.Hypercortisolism, also known as Cushings syndrome,...
Corcept Therapeutics Inc’s Comment on Sales, Marketing and Customers
Pharmaceutical and biotechnology companies are subject to regulatory statutes governing the promotion and marketing of their products. These companies engage with federal health care programs and healthcare providers, including physicians, pharmacies, teaching hospitals, and various practitioners such as doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants, and certified nurse midwives. Under the federal Physician Payments Sunshine Act, drug manufacturers are required to report payments or transfers of value made to these healthcare organizations and practitioners.
Sources:
Corcept Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Corcept Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Corcept Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
145.81 %